Trial Profile

A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) to Determine the Feasibility and Safety of Intratumoral Injection With or Without Intramural Injection in Subjects With Bladder Cancer

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 17 Apr 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

04 Dec 2025 Planned End Date changed from 1 Apr 2027 to 1 Mar 2027.
04 Dec 2025 Planned primary completion date changed from 1 Dec 2026 to 1 Mar 2027.
13 Nov 2025 According to an Aura Biosciences media release, Data Presented at the 45th Congress of the Societe Internationale Urologie (SIU) presented by Seth P. Lerner, M.D., Professor of Urology at Baylor College of Medicine at SIU, held October 29 November 1, 2025, in Edinburgh, United Kingdom

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com